ng slots
Canadian facing ‘exponential’ rise in fraud as holidays, ail strike collide
The year in review: Influential people who died in 2024Swiss National Bank trimmed its holdings in shares of Globus Medical, Inc. ( NYSE:GMED – Free Report ) by 1.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 219,977 shares of the medical device company’s stock after selling 2,300 shares during the period. Swiss National Bank owned about 0.16% of Globus Medical worth $15,737,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GMED. Select Equity Group L.P. bought a new position in Globus Medical during the 2nd quarter worth about $91,711,000. Millennium Management LLC grew its holdings in Globus Medical by 1,171.5% during the 2nd quarter. Millennium Management LLC now owns 1,363,834 shares of the medical device company’s stock worth $93,409,000 after acquiring an additional 1,256,570 shares in the last quarter. Artemis Investment Management LLP bought a new position in Globus Medical during the 3rd quarter worth about $30,656,000. Victory Capital Management Inc. lifted its position in shares of Globus Medical by 855.3% during the second quarter. Victory Capital Management Inc. now owns 381,253 shares of the medical device company’s stock valued at $26,112,000 after buying an additional 341,342 shares during the last quarter. Finally, Swedbank AB purchased a new stake in shares of Globus Medical during the first quarter valued at about $17,433,000. 95.16% of the stock is currently owned by institutional investors. Analyst Ratings Changes Several analysts have commented on GMED shares. Piper Sandler increased their price target on shares of Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Barclays increased their price target on shares of Globus Medical from $85.00 to $93.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th. Morgan Stanley increased their price target on shares of Globus Medical from $74.00 to $83.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Royal Bank of Canada increased their price target on shares of Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. Finally, BTIG Research increased their price objective on shares of Globus Medical from $77.00 to $78.00 and gave the company a “buy” rating in a research report on Monday, October 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.18. Insider Buying and Selling In other news, Director Ann D. Rhoads sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $70.36, for a total transaction of $1,055,400.00. Following the sale, the director now owns 42,884 shares of the company’s stock, valued at $3,017,318.24. This trade represents a 25.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . Also, CEO Daniel T. Scavilla sold 60,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $80.02, for a total transaction of $4,801,200.00. The disclosure for this sale can be found here . In the last quarter, insiders have sold 110,000 shares of company stock worth $8,512,850. 18.54% of the stock is owned by company insiders. Globus Medical Trading Down 0.2 % Shares of NYSE:GMED opened at $84.72 on Friday. Globus Medical, Inc. has a twelve month low of $44.02 and a twelve month high of $85.30. The company’s 50 day moving average is $74.76 and its 200 day moving average is $70.69. The company has a market cap of $11.54 billion, a PE ratio of 126.45, a price-to-earnings-growth ratio of 1.99 and a beta of 1.17. Globus Medical ( NYSE:GMED – Get Free Report ) last issued its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.18. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The company had revenue of $625.71 million for the quarter, compared to the consensus estimate of $604.69 million. During the same quarter in the prior year, the company earned $0.57 EPS. Globus Medical’s quarterly revenue was up 63.1% on a year-over-year basis. Equities research analysts predict that Globus Medical, Inc. will post 2.98 earnings per share for the current fiscal year. Globus Medical Company Profile ( Free Report ) Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. Read More Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter .
PHILADELPHIA and PERTH, Australia , Dec. 23, 2024 /PRNewswire/ -- Arcadium Lithium plc (NYSE: ALTM, ASX: LTM, "Arcadium Lithium"), a leading global lithium chemicals producer, today announced that it has obtained all requisite shareholder approvals in connection with the proposed acquisition by Rio Tinto previously announced on October 9 , 2024. "Today's vote of support by our shareholders confirms our shared belief that with Rio Tinto, we will be a stronger global leader in lithium chemicals production. Together, we enhance our capabilities to successfully develop and operate our assets while supporting the clean energy transition. We are confident that this transaction will provide future benefit to our customers, employees and the communities in which we operate, and I am excited by the path ahead," said Paul Graves , president and chief executive officer of Arcadium Lithium. The final voting results of Arcadium Lithium's special meetings will be filed with the Securities and Exchange Commission in a Form 8-K and will also be available at https://ir.arcadiumlithium.com . Regulatory Update As of this release, merger control clearance has been satisfied or waived in Australia , Canada , China , the United Kingdom and the United States (Hart-Scott-Rodino Antitrust Improvements Act of 1976). Additionally, investment screening approval has been satisfied in the United Kingdom . The proposed transaction is still expected to close in mid-2025, subject to the receipt of remaining regulatory approvals and other closing conditions. Arcadium Lithium Contacts Investors: Daniel Rosen +1 215 299 6208 daniel.rosen@arcadiumlithium.com Phoebe Lee +61 413 557 780 phoebe.lee@arcadiumlithium.com Media: Karen Vizental +54 9 114 414 4702 karen.vizental@arcadiumlithium.com About Arcadium Lithium Arcadium Lithium is a leading global lithium chemicals producer committed to safely and responsibly harnessing the power of lithium to improve people's lives and accelerate the transition to a clean energy future. We collaborate with our customers to drive innovation and power a more sustainable world in which lithium enables exciting possibilities for renewable energy, electric transportation and modern life. Arcadium Lithium is vertically integrated, with industry-leading capabilities across lithium extraction processes, including hard-rock mining, conventional brine extraction and direct lithium extraction (DLE), and in lithium chemicals manufacturing for high performance applications. We have operations around the world, with facilities and projects in Argentina , Australia , Canada , China , Japan , the United Kingdom and the United States . For more information, please visit us at www.ArcadiumLithium.com . Important Information and Legal Disclaimer: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this news release are forward-looking statements. In some cases, we have identified forward-looking statements by such words or phrases as "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words and phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for Arcadium Lithium based on currently available information. There are important factors that could cause Arcadium Lithium's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including the completion of the transaction on anticipated terms and timing, including obtaining required regulatory approvals, and the satisfaction of other conditions to the completion of the transaction; potential litigation relating to the transaction that could be instituted by or against Arcadium Lithium or its affiliates, directors or officers, including the effects of any outcomes related thereto; the risk that disruptions from the transaction will harm Arcadium Lithium's business, including current plans and operations; the ability of Arcadium Lithium to retain and hire key personnel; potential adverse reactions or changes to business or governmental relationships resulting from the announcement or completion of the transaction; certain restrictions during the pendency of the transaction that may impact Arcadium Lithium's ability to pursue certain business opportunities or strategic transactions; significant transaction costs associated with the transaction; the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the occurrence of any event, change or other circumstance that could give rise to the termination of the transaction, including in circumstances requiring Arcadium Lithium to pay a termination fee or other expenses; competitive responses to the transaction; the supply and demand in the market for our products as well as pricing for lithium and high-performance lithium compounds; our ability to realize the anticipated benefits of the integration of the businesses of Livent and Allkem or of any future acquisitions; our ability to acquire or develop additional reserves that are economically viable; the existence, availability and profitability of mineral resources and mineral and ore reserves; the success of our production expansion efforts, research and development efforts and the development of our facilities; our ability to retain existing customers; the competition that we face in our business; the development and adoption of new battery technologies; additional funding or capital that may be required for our operations and expansion plans; political, financial and operational risks that our lithium extraction and production operations, particularly in Argentina , expose us to; physical and other risks that our operations and suppliers are subject to; our ability to satisfy customer qualification processes or customer or government quality standards; global economic conditions, including inflation, fluctuations in the price of energy and certain raw materials; the ability of our joint ventures, affiliated entities and contract manufacturers to operate according to their business plans and to fulfill their obligations; severe weather events and the effects of climate change; extensive and dynamic environmental and other laws and regulations; our ability to obtain and comply with required licenses, permits and other approvals; and other factors described under the caption entitled "Risk Factors" in Arcadium Lithium's 2023 Form 10-K filed with the SEC on February 29, 2024 , as well as Arcadium Lithium's other SEC filings and public communications. Although Arcadium Lithium believes the expectations reflected in the forward-looking statements are reasonable, Arcadium Lithium cannot guarantee future results, level of activity, performance or achievements. Moreover, neither Arcadium Lithium nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Arcadium Lithium is under no duty to update any of these forward-looking statements after the date of this news release to conform its prior statements to actual results or revised expectations . View original content to download multimedia: https://www.prnewswire.com/news-releases/arcadium-lithium-announces-shareholder-approval-of-proposed-rio-tinto-transaction-and-provides-regulatory-update-302338409.html SOURCE Arcadium Lithium PLCBiden's Thanksgiving holiday is part of a longer farewell as Trump's return to White House nearsPaylocity Holding Co. ( NASDAQ:PCTY – Get Free Report ) has received an average recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $196.64. Several research analysts have commented on the company. Mizuho boosted their target price on Paylocity from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Barclays upped their price objective on Paylocity from $174.00 to $180.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial upped their price objective on Paylocity from $195.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Jefferies Financial Group upped their price objective on Paylocity from $200.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, BMO Capital Markets upped their price objective on Paylocity from $175.00 to $203.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Read Our Latest Report on Paylocity Paylocity Stock Up 1.7 % Insider Buying and Selling at Paylocity In other Paylocity news, SVP Rachit Lohani sold 658 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $162.83, for a total transaction of $107,142.14. Following the transaction, the senior vice president now directly owns 39,764 shares in the company, valued at approximately $6,474,772.12. This represents a 1.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link . Also, Director Steven I. Sarowitz sold 15,444 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $195.43, for a total value of $3,018,220.92. Following the transaction, the director now owns 9,272,906 shares in the company, valued at $1,812,204,019.58. The trade was a 0.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last 90 days, insiders sold 59,971 shares of company stock valued at $11,750,096. 21.91% of the stock is currently owned by company insiders. Hedge Funds Weigh In On Paylocity Institutional investors and hedge funds have recently modified their holdings of the business. Coldstream Capital Management Inc. bought a new position in shares of Paylocity in the 3rd quarter worth $239,000. Geode Capital Management LLC increased its holdings in Paylocity by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,048,806 shares of the software maker’s stock worth $173,053,000 after buying an additional 36,590 shares during the last quarter. Vestcor Inc raised its position in Paylocity by 943.8% in the third quarter. Vestcor Inc now owns 10,000 shares of the software maker’s stock worth $1,650,000 after acquiring an additional 9,042 shares during the period. Barclays PLC raised its position in Paylocity by 14.3% in the third quarter. Barclays PLC now owns 44,897 shares of the software maker’s stock worth $7,407,000 after acquiring an additional 5,609 shares during the period. Finally, Public Employees Retirement System of Ohio raised its position in Paylocity by 30.0% in the third quarter. Public Employees Retirement System of Ohio now owns 65,408 shares of the software maker’s stock worth $10,790,000 after acquiring an additional 15,092 shares during the period. 94.76% of the stock is currently owned by institutional investors. About Paylocity ( Get Free Report Paylocity Holding Corporation engages in the provision of cloud-based human capital management and payroll software solutions for workforce in the United States. The company offers payroll software solution for global payroll, expense management, tax services, on demand payment, and garnishment managed services; and time and labor management software for time and attendance, scheduling, and time collection. Read More Receive News & Ratings for Paylocity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paylocity and related companies with MarketBeat.com's FREE daily email newsletter .
Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Stock market today: Rising tech stocks pull Wall Street to another recordOne of the big differences between the not-for-profit sector, which my company Our Community works with, and the frankly commercial sector is that ?" and for-profits ask "What can we get away with?". or signup to continue reading That's not an anti-capitalist rant. Businesses work in the real world, and NFPs need to learn from them. Laws aren't granite walls that channel us in a set direction. They're more like wetlands. You can take the made road through, and most people do, but if you have a reason to go another route you can generally feel your way through the bogs without actually hitting the unmapped patches of quicksand. All laws are unavoidably ambiguous, and lawyers don't give definitive answers. How could they? Every single court case since the ancient Mesopotamians thought up the idea of courts in the first place has involved two people who both believed, on consideration of the relevant texts, that they were in the right. In the light of this, it's clear that a perfect dispute resolution system, managed by angels, might achieve a client satisfaction rate as high as 50 per cent. Under a totally corrupt system run by ignorant morons, that rate might sink as low as 50 per cent. I'd say Australia fell somewhere in the middle. Like so much else in life, lawyers are primarily a means of assessing risk. Their job is to find out what degree of risk you're happy with and direct you along a vector that points towards your eventual goals. Along the way, your course is going to be pushed or pulled one way or another by the force fields that apply to all of us all the time; the law, yes, but also cost, degree of difficulty, time, paperwork, and, above all, other people. At Our Community we get a stream of inquiries from clubs and societies asking variations on the same question: "Our constitution says such-and-such, but that's not going to work. What do we do?" To which we generally bounce back another question: "Who cares?" That's not a flippant dismissal (well, not always). It's a vital constitutional principle, at all levels. If nobody has an interest in taking you down, you can fairly safely choose your own course. If the rules have painted you into a corner, people will generally look the other way even though you're tracking paint through the corridor (and who does paint their floors, anyway? Haven't you ever heard of carpeting?). If your problem involves significant amounts of money, of course, people are likely to care, but most volunteer NFPs can't hope in their wildest dreams to run into those hazards. Most of the time, they just want to be good citizens. And it's here that they run into the government information fogbank. If you go to any government website or helpline with a difficult question, you'll find that the exchange goes something like this. "Your site says 'Twas brillig, and the slithy toves did gyre and gimble in the wabe: All mimsy were the borogoves, And the mome raths outgrabe.' Does that apply to my group?" "Your call is important to us. If, in your case, you are brillig, and the slithy toves did gyre and gimble in the wabe: All mimsy were the borogoves, and the mome raths outgrabe, then yes. Otherwise, no." Jargon, legalese, poor drafting - there is a whole range of things that can make the written rules unreadable. Still, no government advice source can either add or subtract a jot or tittle from the words of the act, and so it can't say what the words mean, and so the answers don't touch on anything the questioner wants to know. That's where the Our Community advice line comes in. We're generally prepared to give a three-dimensional answer, lifting off the page into the real world. Most of law, we tell people with questions, is a bluff. If you park illegally, or evade your tram fare, or put soft plastics into your recycling bin, you'll very probably get away with it, and those offences actually have enforcement officers who want to justify their salaries by feeling the collars of as many malefactors as possible. NFPs don't have even that. The regulators are first and foremost concerned with having their forms filled out correctly, and they will intervene only if the NFP concerned is overturned in the middle lane of the freeway leaking petrol while setting off fireworks. Which is, to a large extent, a good thing. Nearly all NFPs are trying to do the right thing nearly all the time, and forcing them into rigid compliance would be simply a waste of everybody's time and money, with the added possibility of political abuses. We should trust them. That involves a risk that some groups will abuse that trust, yes - a very small risk - but the alternative is grisly. NFPs should be focusing on what they want to do, which is to make Australia a better place, rather than on what's in the small print. DAILY Today's top stories curated by our news team. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily! Advertisement Advertisement
HIGH POINT, N.C. (AP) — D'Maurian Williams scored 18 points as High Point beat Pfeiffer 81-50 on Saturday. Williams went 8 of 13 from the field (2 for 3 from 3-point range) for the Panthers (8-1). Kezza Giffa scored 14 points, going 3 of 8 from the floor, including 1 for 3 from 3-point range, and 7 for 8 from the line. Kimani Hamilton shot 4 for 8, including 1 for 3 from beyond the arc to finish with 11 points. The Falcons were led by Doug Smith and Justin Gaten with nine points apiece. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar . For copyright information, check with the distributor of this item, Data Skrive.
NoneFirst Published: 30th November, 2024 20:51 IST "Zo" Identity Would Help Bridge Gaps and Foster Sense of Solidarity Among Mizos: Mizoram CM Lalduhoma Mizoram Chief Minister Lalduhoma, in an address at the International Chin Christian Youth Conference at Lawngtlai on Thursday, underscored the importance of unity, both in faith and in political solidarity, while drawing deep historical connections to the region’s past. The Mizoram Chief Minister said that the terms “Lushai,” “Chin,” and “Kuki” were imposed externally by the British, leading to misunderstandings and divisions among ethnic brothers. COMMENTS Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Your email address will not be published. Required fields are marked * Comment * Name * Email * Website